Abstract
The current standard of care for a fungal central venous catheter infection in a pediatric patient usually requires removal without any other feasible options. Although removal may reduce the rate of Candida-associated complications, literature reviews question whether the outcomes of removal substantiate this being the standard of care. We report 6 cases of central venous catheter fungal infections treated with liposomal amphotericin-B lock therapy. These cases consisted of 4 patients, 2 of whom received recurrent therapy. In 4 of these cases, there was successful eradication of the infectious fungal agent, allowing continued use of the catheter. A controlled study of antifungal lock therapy should be considered as a potential alternative to removal.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 762-764 |
| Number of pages | 3 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 27 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antifungal lock therapy
- Central venous catheters
- Fungal infections
- Liposomal amphotericin-B
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS